

TAF-I β deficiency inhibits proliferation and promotes apoptosis by rescuing PP2A and inhibiting the AKT/GSK-3 β pathway in leukemic cells

YANFENG LIU¹, YAN JIA¹, XIAO FU¹ and PENGCHENG HE²

¹Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan 410008;

²Department of Hematology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China

Received February 24, 2019; Accepted July 16, 2019

DOI: 10.3892/etm.2019.8012

Abstract. Template-activating factor I β (TAF-I β) has been associated with numerous pathophysiological processes and has been reported as an oncogene responsible for the regulation of important signaling pathways in various types of solid tumor; however, few studies have investigated the role of TAF-I β in leukemia. The present study reported the upregulated expression of TAF-I β in 36 patients with acute leukemia and six leukemic cell lines. In addition, TAF-I β -knockdown (KD) cells were generated via RNA interference. TAF-I β KD not only inhibited the proliferation of leukemia cells but also induced apoptosis. Furthermore, it was revealed that the mechanism underlying these effects may be associated with the upregulation of protein phosphatase type 2A and inhibition of the protein kinase B/glycogen synthase kinase-3 β signaling pathway. Collectively, the findings demonstrated that TAF-I β serves an important role in various types of leukemia and may be considered as a potential therapeutic target for the treatment of leukemia.

Introduction

Leukemia is recognized as one of the most common types of human malignancy (1). Globally, ~30,000 new cases are diagnosed and >23,000 patients succumb annually as a result of this disease (2). Among children with cancer, almost one-third of cases are diagnosed as a type of leukemia (3). In addition, leukemia is the second most common form of cancer in infants (<1-year-old) and first most common in older children (4). Despite developments in various therapeutic strategies, chemotherapy is administered as a first-line therapy and has

a high rate of remission. Of note, disease recurrence and drug resistance often occur during the first year of treatment (5). As the overall survival rate of patients with leukemia is poor, there is an urgent need to screen and identify novel therapeutic targets for the treatment of this disease (6).

Protein phosphatase type 2A (PP2A) is a broad specificity serine/threonine phosphatase, which acts as a regulator of various biological processes. Its loss of function has been associated with signaling pathways involved in cancer, including the mitogen-activated protein kinase (MAPK) kinase/extracellular signal-regulated kinase and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) cascades (7). Template-activating factor I β (TAF-I β) is a potent physiological inhibitor of PP2A and a multifunctional protein with a role in various cellular processes, including DNA replication, RNA splicing chromatin remodeling and nucleosome assembly (8). In addition, TAF-I β has been reported to inhibit the tumor suppressor NM23-H1, an activator of the AP-1/MAPK signaling pathway (9); NM23-H1 regulates the production of granzyme B and interferon- γ (10). Additionally, it has been suggested that TAF-I β is an oncogene involved in several types of solid tumor, including those in lung cancer, cervical cancer, renal carcinoma, gastric carcinoma, colorectal cancer and non-Hodgkin's lymphoma (11); however, the role of TAF-I β in the development of leukemia requires further investigation.

Our previous study using comparative proteomics revealed that TAF-I β is a differentially expressed protein that is involved in arsenic trioxide-related cell survival in acute promyelocytic leukemia (Fig. S1) (12). In the present study, whether TAF-I β is differentially expressed in other leukemia subtypes, and its effects on cell proliferation and apoptosis were investigated. Furthermore, the underlying molecular mechanism was determined, which may provide a theoretical basis for the development of targeted therapeutic approaches for treating leukemia.

Materials and methods

Cell line and culture. Leukemia can be divided into acute leukemia and chronic leukemia. Both can be further divided into lymphocytic leukemia and myeloid leukemia. In addition,

Correspondence to: Dr Yanfeng Liu, Department of Hematology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan 410008, P.R. China
E-mail: liu_xiaoyu2@163.com

Key words: template-activating factor I β , protein phosphatase 2A, glycogen synthase kinase-3 β , apoptosis, leukemia

acute myeloid leukemia can be divided into M0-M7 according to the FAB classification criteria (13). Therefore, leukemia is a complex hematological malignant tumor, and each subtype has its own unique features. In the present study, six leukemia cell lines were used, namely the Jurkat human T cell acute lymphoblastic leukemia cell line, the BALL-1 B cell acute lymphoblastic leukemia cell line, the NB4, HL-60 and THP-1 acute myeloid leukemia cell lines and the K562 chronic myeloid leukemia cell line. All cell lines were donated by the Shanghai Institute of Hematology (Shanghai, China). The cells were routinely cultured in RPMI 1640 medium supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) in a humidified incubator containing 5% CO_2 at 37°C, as previously described (14). SC79 was provided by Selleck Chemicals.

Patient samples. Primary bone marrow samples were obtained from the inpatient and outpatient departments of Xiangya Hospital of Central South University (Changsha, China). A total of 36 patients with acute leukemia and 30 normal controls (healthy individuals without hematological conditions or other solid tumors) were included for tissue collection between 2016 and 2018; the patient characteristics are presented in Table I. Diagnosis was performed according to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Acute lymphoblastic/myeloid leukemia (version 1.2015, <https://www.nccn.org>). Clinical data were collected from medical clinical records. The present study was approved by the Ethics Committee of Xiangya Hospital (approval no. 201603063).

Cell transfection. Lentiviral vector construction was performed as previously reported (15). Briefly, short hairpin RNA (shRNA) against the human TAF- $\text{I}\beta$ gene [shRNA-knockdown (KD)] and scramble shRNA, which acts as a negative control (shRNA-NC), were constructed by Shanghai GeneChem Co., Ltd. (Shanghai, China). The leukemic cells were then transfected with the shRNA-KD or shRNA-NC vectors using Lipofectamine® 2000. The green fluorescent protein (GFP)-positive cells were counted under a fluorescence microscope. The RNA interference efficiency was evaluated by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analyses.

RT-qPCR analysis. Total RNA was extracted using an RNAfast200 kit (Fastagen, Shanghai, China). RT was performed with a One Step SYBR PrimeScript™ RT-PCR kit (Takara Biotechnology Co., Ltd., Dalian, China). The thermocycling conditions were as follows: 52°C for 5 min, 95°C for 10 sec. The primers sequences were as follows: TAF- $\text{I}\beta$, forward 5'-AAATATAACAAACCTCCGCCAACCC-3', reverse, 5'-CAGTGCCTCTTCATCTTCCTC-3' and GAPDH, forward 5'-TGCACCACCAATGCTTAG-3' and reverse 5'-GGATGCAGGGATGATGTTC-3'. The thermocycling conditions were as follows: 95°C for 5 sec, 60°C for 30 sec and 40 cycles, 4°C for 30 min and end of the PCR reaction. GAPDH was used for normalization; expression levels were quantified via the $2^{-\Delta\Delta\text{Cq}}$ method (16).

Western blot analysis. The specific experimental process of western blotting was performed according to our previous

Table I. Clinical characteristics of a series of 36 patients with acute leukemia.

Clinical and molecular characteristics	N	%
Sex		
Male	15	41.7
Female	21	58.3
Age (years)		
<60	26	72.2
≥60	10	27.8
ECOG score		
0-2	30	83.3
3-4	6	16.7
Leukemia type		
Acute myeloid leukemia		
M2	9	25.0
M3	7	19.4
M4	4	11.1
M5	7	19.4
Acute lymphoblastic leukemia		
B-cell	5	13.9
T-cell	4	11.1

ECOG, Eastern Cooperative Oncology Group.

study (14). Briefly, the cells were washed with pre-cooled PBS, following which protein (30 μg) was extracted with radioimmunoprecipitation assay lysis buffer via centrifugation (5,000 \times g for 20 min at 4°C), and separated by 12% SDS-PAGE. Following electrophoresis, the proteins were transferred onto nitrocellulose membranes and incubated with primary antibodies at room temperature for 2 h and 4°C overnight. The antibodies used were as follows: Anti-TAF- $\text{I}\beta$ (cat. no. ab181990, mouse monoclonal, 1:1,000; Abcam, Cambridge, MA, USA), anti-PP2A (cat. no. ab32141, rabbit monoclonal, 1:5,000; Abcam), phosphorylated-glycogen synthase kinase-3 β (GSK-3 β ; Ser9; cat. no. 9336, rabbit monoclonal, 1:1,000; Cell Signaling Technology, Inc., Danvers, MA, USA), phosphorylated-AKT (Ser473; cat. no. 9271, rabbit monoclonal, 1:2,000; Cell Signaling Technology, Inc.), anti-caspase-3 (cat. no. 9662), anti-poly(ADP-ribose) polymerase (PARP; cat. no. 9542, rabbit polyclonal, 1:1,000; Cell Signaling Technology, Inc.) and anti-GAPDH (cat. no. sc-166574, mouse monoclonal, 1:5,000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA). Subsequently, the washed membranes were incubated with secondary antibodies (cat. no. sc-2005; goat anti-mouse or cat. no. sc-2004; goat anti-rabbit IgG, 1:10,000; Santa Cruz Biotechnology, Inc.) for 1 h at room temperature and visualized via chemiluminescence (Bio-Rad chemiluminescence imaging system; Bio-Rad Laboratories, Inc.).

Cell proliferation assay. Cell proliferation was analyzed using a Cell Counting Kit-8 (CCK-8) assay (Dojindo Molecular Technologies, Inc., Kumamoto, Japan), which was performed




Figure 1. TAF-I β is upregulated in leukemia. (A) Western blot analysis of the protein expression levels of TAF-I β in normal HBMSCs and six leukemic cell lines. (B) RT-qPCR analysis of the mRNA levels of TAF-I β in HBMSCs and six leukemic cell lines. (C) RT-qPCR analysis of the mRNA levels of TAF-I β in acute leukemia and normal control specimens. *P<0.05 vs. HBMSCs, **P<0.01 vs. normal control. HBMSCs, human bone marrow mesenchymal stem cells; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; TAF-I β , template-activating factor I β .




Figure 2. Lentiviral vector transfection efficiency and expression of TAF-I β in six leukemic cell lines. (A) Green fluorescent protein-positive cells as detected by fluorescence microscopy (magnification, x200). (B) Protein expression of TAF-I β was detected by western blotting. (C) mRNA expression of TAF-I β as detected by reverse transcription-quantitative polymerase chain reaction analysis. **P<0.01 vs. CON. TAF-I β , template-activating factor I β ; CON, control; KD, knockdown.

according to the manufacturer's protocol. A total of 100 μ l of cell suspension (5,000 cells/well) was inserted into a 96-well plate and the cells were cultured at 37°C in 5% CO₂ for 48 h. Following culture, 10 μ l CCK-8 solution was applied to each well of the plate and cells were incubated for 3 h in an incubator at 37°C. Subsequently, the absorbance was measured at

450 nm using a multifunctional microplate reader (BioTek Instruments, Inc., Winooski, VT, USA).

Colony formation assay. This assay was performed using semisolid methylcellulose medium (Stemcell Technologies, Inc., Vancouver, BC, Canada) as previously described (17).




Figure 3. Template-activating factor I β KD significantly inhibits leukemic cell growth and induces cell cycle arrest. Cell proliferation as detected by (A) Cell Counting Kit-8 and (B) colony formation assays (magnification, x40). (C) Percentages of G₀/G₁-, S- and G₂/M-phase cells as detected by flow cytometry. *P<0.05, **P<0.01 vs. CON. KD, knockdown; CON, control; NC, negative control.

Flow cytometry (FCM). Each group of cells were washed with pre-cooled PBS three times, following which the cell cycle and apoptosis were analyzed according to the manufacturer's protocols of the cell cycle staining and Annexin V-phycoerythrin/7-aminoactinomycin D apoptosis kits (Multi Sciences, Hangzhou, China), respectively, with a BD FACScan flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). For cell cycle analysis, $\sim 1 \times 10^6$ cells were incubated with 1 ml DNA staining solution and 10 μ l permeabilization solution. The cells were vortexed for 10 sec and incubated in the dark at room temperature for 30 min and analyzed. For the detection of apoptotic cells, 3×10^6 untreated cells were resuspended with 500 μ l apoptosis-positive control solution. Following incubation on ice for 30 min, the supernatant was discarded. Subsequently, 1.5 ml 1X binding buffer was added. This cell suspension was divided into three groups, labeled as the blank control, single staining A (5 μ l Annexin-fluorescein isothiocyanate staining for 5 min without light) and single staining

B (10 μ l propidium iodide staining for 5 min without light) groups. Subsequently, the parameters for FCM (488 nm excitation and band pass filters of 530/30 nm for FITC detection and 585/42 nm for 7-AAD detection) were set for the analysis of the aforementioned cell groups. As the six leukemia cell lines all underwent the same treatment. The flow parameters of each cell line were not set separately. Although this may result in a high background state in certain cell lines, it does not cause a qualitative change in the final statistical results. Based on these criteria, all other analyses were performed.

Statistical analysis. All statistical evaluations were performed using SPSS software (version 22.0; IBM Corp., Armonk, NY, USA); analyses were repeated at least three times. Statistical significance was determined using Student's t-test or one-way analysis of variance (followed by the LSD post hoc test). P<0.05 was considered to indicate a statistically significant difference.




Figure 4. TAF-I β KD induces leukemic cell apoptosis. (A) Apoptotic rate of TAF-I β -KD and CON groups of leukemic cell lines as determined by flow cytometric analysis. (B) Protein expression of caspase-3 and PARP in TAF-I β KD and CON groups of leukemic cell lines as detected by western blot analysis. *P<0.05 vs. CON, **P<0.01 vs. CON. PARP, poly (ADP-ribose) polymerase; TAF-I β , template-activating factor I β ; KD, knockdown; CON, control.

Results

TAF-I β is upregulated in leukemic cells and patients with leukemia. The expression of TAF-I β was examined in six typical leukemic cell lines and normal human bone marrow mesenchymal stem cells (HBMSCs). The western blot

(Fig. 1A) and RT-qPCR (Fig. 1B) analyses revealed increased expression levels of TAF-I β in almost all leukemic cell lines compared with those in the HBMSCs. Additionally, the RT-qPCR analysis of clinical samples from 36 patients with acute leukemia and 30 normal controls demonstrated that 72.2% of the leukemic bone marrow specimens




Figure 5. TAF- $\text{I}\beta$ KD upregulates the expression of PP2A and inhibits the AKT/GSK-3 β signaling pathway in NB4 and K562 cells. (A) Expression of PP2A in TAF- $\text{I}\beta$ KD and CON groups. (B) Expression of GSK-3 β and pGSK-3 β (Ser9). (C) Expression of AKT and pAKT(Ser473) in cells with or without SC79 treatment. (D) Expression of GSK-3 β and pGSK-3 β (Ser9) in cells with or without SC79 treatment. * $P < 0.05$ and ** $P < 0.01$ vs. CON. TAF- $\text{I}\beta$, template-activating factor $\text{I}\beta$; AKT, protein kinase B; pAKT(Ser473), Ser473-phosphorylated AKT; KD, knockdown; CON, control; GSK-3 β , glycogen synthase kinase-3 β ; pGSK-3 β (Ser9), Ser9-phosphorylated GSK-3 β ; PP2A, protein phosphatase type 2A.

(26/36 samples) exhibited upregulated expression of TAF- $\text{I}\beta$. By contrast, the normal control specimens exhibited relatively low expression (Fig. 1C).

Generation of leukemic cells with TAF- $\text{I}\beta$ KD. In order to determine whether TAF- $\text{I}\beta$ serves a functional role in leukemic cells, shRNA-KD or shRNA-NC were transfected into the Jurkat, BALL-1, NB4, HL-60, THP-1 and K562 cells. The results demonstrated that the transfection efficiency (GFP-positive cell count) was $>80\%$ (Fig. 2A). In addition, the mRNA and protein expression levels of TAF- $\text{I}\beta$ were significantly decreased in the KD groups compared with those in the CON groups ($P < 0.01$; Fig. 2B and C).

TAF- $\text{I}\beta$ KD significantly inhibits leukemic cell growth and induces cell cycle arrest. To evaluate the effects of TAF- $\text{I}\beta$ KD on leukemic cell proliferation *in vitro*, a CCK-8 assay was performed. The results revealed that, compared with those of the CON and NC groups, the proliferative abilities of cells in the KD groups were significantly inhibited ($P < 0.05$; Fig. 3A). In accordance with these findings, TAF- $\text{I}\beta$ KD in the cells led to decreases in the number and size of colonies ($P < 0.05$; Fig. 3B). By contrast, analysis by FCM indicated that the percentages of S-phase Jurkat, BALL-1 and HL-60 cells in the KD groups were notably reduced compared with those in the CON groups; the numbers of G_0/G_1 - or G_2/M -phase cells were significantly increased ($P < 0.01$; Fig. 3C).

TAF- $\text{I}\beta$ KD induces leukemia cell apoptosis. The results of the present study demonstrated that the apoptotic rates of the Jurkat, BALL-1, NB4, HL-60, THP-1 and K562 cells in the KD groups were 21.51 ± 0.77 , 27.33 ± 0.77 , 61.67 ± 0.77 , 35.70 ± 0.77 , 15.48 ± 0.77 and $40.55 \pm 0.77\%$, respectively, which was notably higher than those in the corresponding control

groups (Fig. 4A). Additionally, the expression levels of cleaved caspase-3 (p19) and PARP (p89) were significantly increased compared with those in the CON groups, indicating the induction of apoptosis ($P < 0.01$; Fig. 4B).

TAF- $\text{I}\beta$ KD upregulates the expression of PP2A and inhibits the AKT/GSK-3 β signaling pathway. TAF- $\text{I}\beta$ was originally identified as a potent physiological inhibitor of PP2A; therefore, the expression levels of PP2A were determined following TAF- $\text{I}\beta$ silencing. As expected, TAF- $\text{I}\beta$ KD resulted in upregulated expression levels of PP2A ($P < 0.05$; Fig. 5A). Additionally, as TAF- $\text{I}\beta$ may be associated with the expression of GSK-3 β in cancer and diseases of the central nervous system (18), alterations in the expression of GSK-3 β were analyzed in NB4 and K562 cells. TAF- $\text{I}\beta$ KD appeared to inhibit the phosphorylation of GSK-3 β , as demonstrated by reductions in the levels of Ser9-phosphorylated GSK-3 β ($P < 0.05$; Fig. 5B). To further investigate the mechanism regulating the expression of GSK-3 β , the expression of AKT was analyzed, which is a well-known kinase that is activated by various factors and is involved in the regulation of cell proliferation, differentiation, metastasis and apoptosis (19). The results demonstrated that TAF- $\text{I}\beta$ KD markedly inhibited the expression of AKT; this effect was reversed by SC79, an inducer of AKT. Additionally, the TAF- $\text{I}\beta$ KD-mediated downregulation of GSK-3 β was suppressed following treatment with SC79 ($P < 0.01$; Fig. 5C and D).

Discussion

The upregulation of TAF- $\text{I}\beta$ has been detected in several solid tumors and has been associated with increased invasion and poor outcome (20). In addition, TAF- $\text{I}\beta$ deficiency has been shown to decrease cell growth in various types of cancer (21);

however, this does not occur in all types of tumor. For example, this inhibitory effect on cell growth has not been observed in primary canine melanoma (22). This suggests that TAF-I β may exhibit opposing effects on cell survival in different types of cancer (23). The role of TAF-I β has been reported extensively; however, the expression of TAF-I β and the effects of its silencing in different subtypes of leukemia require further investigation.

Regarding the mechanism suppressing the development of leukemia, the most commonly reported in the literature is the rescue of PP2A phosphatase activity (20). It is well known that PP2A is a serine/threonine phosphatase and acts as a tumor suppressor. The upregulation of PP2A decreases tumor cell growth and is inhibited by TAF-I β (24). Consistent with this hypothesis, the protein expression of TAF-I β was elevated in patients with different subtypes of leukemia. In addition, TAF-I β deficiency led to significantly increased expression of PP2A and decreased leukemic cell proliferation. PP2A has also been reported to serve as a switch that determines whether cells undergo autophagy or apoptosis. Zhou *et al* (25) suggested that active caspase-3 cleaves the A subunit of PP2A, following which AKT is inactivated by PP2A to promote apoptosis. By contrast, the inactivation of caspase-3 leads to the dissociation of PP2A and AKT; unbound PP2A then interacts with death-associated protein kinase to induce autophagy. Similarly, the present study reported that TAF-I β silencing upregulated the expression of cleaved caspase-3 (p19), down-regulated that of active AKT and induced apoptosis; however, further verification by analyzing the co-localization of PP2A and AKT is required.

Apart from the mitochondrial pathway of apoptosis, leukemic cell death can be induced via TAF-I β deficiency-mediated GSK-3 β inhibition. Of note, GSK-3 β is a downstream mediator of the PI3K/AKT signaling cascade and can be phosphorylated by AKT (26). Numerous studies have reported that GSK-3 β is essential for regulating a series of cellular functions in tumors (27,28); the suppression of GSK-3 β results in the reduced binding of nuclear factor- κ B to its target gene promoters, inducing the apoptosis and/or decreased growth of cells (29,30).

Collectively, the results of the present study demonstrated that the downregulation of TAF-I β may suppress the proliferation and promote the apoptosis of leukemic cells. The mechanisms involved in these processes may be associated with the rescue of PP2A phosphatase activity and inhibition of the AKT/GSK-3 β signaling pathway. These novel findings provide insight into the oncogenic potential of TAF-I β and serve as a basis for future investigations into the function of TAF-I β and the mechanisms underlying its regulatory effects. Therefore, TAF-I β may be considered as a therapeutic target in the treatment of leukemia. A limitation of the present study was that no rescue experiments, involving the overexpression of TAF-I β to overcome TAF-I β deficiency and examine its effect on proliferation and apoptosis, were performed. Rescue experiments warrant inclusion in future investigations to consolidate and further the findings of the present study.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Natural Science Foundation of China (grant nos. 81600135 and 81800680).

Availability of data and materials

The datasets generated and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

YFL designed the study and wrote the manuscript, YJ performed the experiments and XF conducted data analysis; PCH was responsible for data analysis and interpretation. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The use of human bone marrow specimens was approved by the Ethics Committee of Xiangya Hospital (Changsha, China). All patients provide written informed consent.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Zhang DY, Yuan XQ, Yan H, Cao S, Zhang W, Li XL, Zeng H and Chen XP: Association between DCK 35708 T>C variation and clinical outcomes of acute myeloid leukemia in South Chinese patients. *Pharmacogenomics* 17: 1519-1531, 2016.
2. Betz BL and Hess JL: Acute myeloid leukemia diagnosis in the 21st century. *Arch Pathol Lab Med* 134: 1427-1433, 2010.
3. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, Harbott J, Hasle H, Johnston D, Kinoshita A, *et al*: Diagnosis and management of acute myeloid leukemia in children and adolescents: Recommendations from an international expert panel. *Blood* 120: 3187-3205, 2012.
4. Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A, Conter V, Otten J, Ohara A, Versluys AB, *et al*: Outcomes after induction failure in childhood acute lymphoblastic leukemia. *N Engl J Med* 366: 1371-1381, 2012.
5. Yang M, Zeng P, Kang R, Yu Y, Yang L, Tang D and Cao L: S100A8 contributes to drug resistance by promoting autophagy in leukemia cells. *PLoS One* 9: e97242, 2014.
6. Liang H, Zheng QL, Fang P, Zhang J, Zhang T, Liu W, Guo M, Robinson CL, Chen SB, Chen XP, *et al*: Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells. *Sci Rep* 7: 40361, 2017.
7. Kauko O, Imanishi S, Kuleshkiy E, Laajala TD, Yetukuri L, Padzik A, Jumppanen M, Haapaniemi P, Yadav B, Suni V, *et al*: Abstract 5560: Systemic map of protein phosphatase 2A (PP2A)-regulated phosphotargets and drug responses in cancer cells. *Cancer Res* 77: 5560, 2017.
8. Mody HR, Hung SW, Naidu K, Lee H, Gilbert CA, Hoang TT, Pathak RK, Manoharan R, Muruganandan S and Govindarajan R: SET contributes to the epithelial-mesenchymal transition of pancreatic cancer. *Oncotarget* 8: 67966-67979, 2017.
9. Wu M, Yu G, Yan T, Ke D, Wang Q, Liu R, Wang JZ, Zhang B, Chen D and Wang X: Phosphorylation of SET mediates apoptosis via P53 hyperactivation and NM23-H1 nuclear import. *Neurobiol Aging* 69: 38-47, 2018.

10. Trotta R, Ciarlariello D, Dal Col J, Mao H, Chen L, Briercheck E, Yu JH, Zhang JY, Perrotti D and Caligiuri MA: The PP2A inhibitor SET regulates granzyme B expression in human natural killer cells. *Blood* 117: 2378-2384, 2011.
11. Liu H, Gu Y, Wang H, Yin J, Zheng G, Zhang Z, Lu M, Wang C and He Z: Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer. *Oncotarget* 6: 14913-14925, 2015.
12. Liu Y, He P, Liu F, Zhou N, Cheng X, Shi L, Zhu H, Zhao J, Wang Y and Zhang M: Tetra-arsenic tetra-sulfide (As₄S₄) promotes apoptosis in retinoid acid-resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein. *Tumour Biol* 35: 3421-3430, 2014.
13. Sultan C, Deregnaucourt J, Ko YW, Imbert M, D'Agay MF, Gouault-Heilmann M and Brun B: Distribution of 250 cases of acute myeloid leukaemia (AML) according to the FAB classification and response to therapy. *Br J Haematol* 47: 545-551, 1981.
14. He P, Liu Y, Qi J, Zhu H, Wang Y, Zhao J, Cheng X, Wang C and Zhang M: Prohibitin promotes apoptosis of promyelocytic leukemia induced by arsenic sulfide. *Int J Oncol* 47: 2286-2295, 2015.
15. Liu Y, He P, Liu F, Cheng X and Zhang M: Influence of I2PP2A gene silencing by RNA interference on proliferation and apoptosis of human acute promyelocytic leukemia cell line NB4-R1. *Zhonghua Xue Ye Xue Za Zhi* 35: 732-736, 2014 (In Chinese).
16. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
17. Sun QY, Ding LW, Tan KT, Chien W, Mayakonda A, Lin DC, Loh XY, Xiao JF, Meggendorfer M, Alpermann T, *et al*: Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD). *Leukemia* 31: 1-10, 2017.
18. Zhang Y, Ma RH, Li XC, Zhang JY, Shi HR, Wei W, Luo DJ, Wang Q, Wang JZ and Liu GP: Silencing I2PP2A rescues tau pathologies and memory deficits through rescuing PP2A and inhibiting GSK-3 β signaling in human tau transgenic mice. *Front Aging Neurosci* 6: 123, 2014.
19. de Sousa RT, Zanetti MV, Talib LL, Serpa MH, Chaim TM, Carvalho AF, Brunoni AR, Busatto GF, Gattaz WF and Machado-Vieira R: Lithium increases platelet serine-9 phosphorylated GSK-3 β levels in drug-free bipolar disorder during depressive episodes. *J Psychiatr Res* 62: 78-83, 2015.
20. Bayarkhangai B, Noureldin S, Yu L, Zhao N, Gu Y, Xu H and Guo C: A comprehensive and perspective view of oncoprotein SET in cancer. *Cancer Med* 2018, (Epub ahead of print).
21. Jiang SW, Xu S, Chen H, Liu J and Duan P: Oncogenic role of SET/I2PP2A for gynecologic cancers. *Curr Drug Targets* 18: 1152-1157, 2017.
22. Enjoji S, Yabe R, Fujiwara N, Tsuji S, Vitek MP, Mizuno T, Nakagawa T, Usui T, Ohama T and Sato K: The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma. *J Vet Med Sci* 77: 1451-1456, 2015.
23. Sobral LM, Coletta RD, Alberici LC, Curti C and Leopoldino AM: SET/I2PP2A overexpression induces phenotypic, molecular, and metabolic alterations in an oral keratinocyte cell line. *FEBS J* 284: 2774-2785, 2017.
24. Herbert M and Toth A: How meiosis creates the single-copy genome. *Dev Cell* 40: 3-4, 2017.
25. Zhou H, Luo W, Zeng C, Zhang Y, Wang L, Yao W and Nie C: PP2A mediates apoptosis or autophagic cell death in multiple myeloma cell lines. *Oncotarget* 8: 80770-80789, 2017.
26. Lu Y, Lei S, Wang N, Lu P, Li W, Zheng J, Giri PK, Lu H, Chen X, Zuo Z, *et al*: Protective effect of minocycline against ketamine-induced injury in neural stem cell: Involvement of PI3K/Akt and Gsk-3 beta pathway. *Front Mol Neurosci* 9: 135, 2016.
27. Ye Z, Xia P, Cheng ZG and Guo Q: Neuroprotection induced by sevoflurane-delayed post-conditioning is attributable to increased phosphorylation of mitochondrial GSK-3 β through the PI3K/Akt survival pathway. *J Neurol Sci* 348: 216-225, 2015.
28. Wu J, Liao Q, He H, Zhong D and Yin K: TWIST interacts with β -catenin signaling on osteosarcoma cell survival against cisplatin. *Mol Carcinog* 53: 440-446, 2014.
29. Ougolkov AV, Bone ND, Fernandez-Zapico ME, Kay NE and Billadeau DD: Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. *Blood* 110: 735-742, 2007.
30. Ban JO, Kwak DH, Oh JH, Park EJ, Cho MC, Song HS, Song MJ, Han SB, Moon DC, Kang KW and Hong JT: Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone. *Chem Biol Interact* 188: 75-85, 2010.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.